Keymed Biosciences (FRA:64Z) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
49 GF Score
Price €7.90
GF Value €16.65
! 4 Warning Signs
View Full Analysis

What is Keymed Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Keymed Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €55.9 Mil. Keymed Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €33.9 Mil. Keymed Biosciences's annualized EBITDA for the quarter that ended in Jun. 2026 was €389.0 Mil. Keymed Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Keymed Biosciences's Debt-to-EBITDA or its related term are showing as below:

FRA:64Z' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.94   Med: -0.47   Max: 0.61
Current: 0.61

During the past 7 years, the highest Debt-to-EBITDA Ratio of Keymed Biosciences was 0.61. The lowest was -1.94. And the median was -0.47.

FRA:64Z's Debt-to-EBITDA is ranked better than
62.5% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs FRA:64Z: 0.61

Keymed Biosciences  (FRA:64Z) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Keymed Biosciences Debt-to-EBITDA Related Terms

Keymed Biosciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Keymed Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences Debt-to-EBITDA Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Keymed Biosciences Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:64Z vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Keymed Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keymed Biosciences Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Debt-to-EBITDA falls into.


FRA:64Z
49GF Score
Keymed Biosciences Inc FRA:64Z
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keymed Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Keymed Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(63.223867861379 + 32.854922924544) / -49.935632089902
=-1.92

Keymed Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(55.9065607781 + 33.899658264478) / 389.00271674894
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €7.90 is trading 52.6% below its estimated GF Value™ of €16.65.

Key valuation signals for FRA:64Z:

  • Debt-to-EBITDA:
  • GF Value™: €16.65 vs. price of €7.90 (52.6% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
49GF Score

Get the complete analysis for FRA:64Z

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€16.65
GF Value